Pilot Trial on Efficacy of Single Dose Perioperative Intravenous Dexamethasone for Pain Relief After Endoscopic Submucosal Dissection
Early Gastric Cancer or Gastric Adenoma
Conditions: official terms
Stomach Neoplasms
Conditions: Keywords
Endoscopic submucosal dissection, early gastric cancer, pain relief, intravenous dexamethasone, present pain intensity
Study Type
Study Phase
Study Design
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: intravenous dexamethasone Type: Drug
Name: intravenous normal saline Type: Drug
Overall Status
Besides major ESD-related complications, minor adverse events after ESD are also commonly noticed. Pain is one of minor ESD-related complications. . The causes of pain associated with ESD or gastric polypectomy are thought to be associated with transmural burn or transmural air leak. How control localized pain for patients who suffered from pain after ESD is appearing as new medical interests. There are few studies about management strategy for pain after ESD. Glucocorticoids are used to reduce inflammation and tissue damage in various clinical settings including inflammatory disease, rheumatic disease, and so on. The efficacy of glucocorticoids for reducing pain after surgery has recently been investigated. Glucocorticoids are thought to locally inhibit collagen deposition and fibrosis and finally reduce scar-tissue formation. Especially systemic steroids are easy to achieve a continuous effect through stable serum concentrations. If pain was partially associated with acute inflammation, we assumed intravenous dexamethasone could be helpful to relieve pain after ESD based on previous studies. we aimed to assess the efficacy of single dose postoperative intravenous dexamethasone for pain relief after ESD.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 80 Years
Minimum Age: 20 Years
Gender: Both
Criteria: Inclusion Criteria:

- 20 years of age or older

- pathologically diagnosed gastric adenoma or cancer that was eligible for ESD

- patients who gave written informed consent from patients or responsible family members.

Exclusion Criteria:

- patients who take pain killer within 48 hours or regularly at enrollment

- confirmed any other disease which can induce epigastric pain such as peptic ulcer disease and gastroesophageal reflux disease

- multiple gastric lesions for ESD

- history of gastric surgery at enrollment

- severe underlying disease including infection, cardiopulmonary disease, and diabetes.
Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine
Seoul, Korea, Republic of
Status: Recruiting
Contact: Hyuk Lee, MD - 82-2-2228-1996 - leehyuk@yuhs.ac
Start Date
July 2013
Completion Date
February 2014
Yonsei University
Yonsei University
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page